Latest Funding News

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Eclipse Metals has advanced its Greenland rare earths project with expanded drilling and a key licence renewal, while preparing for a NASDAQ dual listing to tap North American investors.

Omnia Metals Group has successfully issued 54 million shares, raising $1.08 million as part of a broader $1.58 million placement. The company now looks to shareholders for approval to complete the remaining share and option issues.

Nick Scali Limited reported a robust $62 million underlying profit for FY25, completed its UK acquisition equity raise, and announced key leadership changes as it eyes accelerated growth in FY26.

Dart Mining’s preliminary IP survey at the Coonambula project reveals promising extensions of the Banshee antimony-gold mineralisation, setting the stage for expanded drilling and resource modelling.

Arafura Rare Earths has successfully raised A$475 million through a two-tranche institutional placement, backed by major investors including Hancock Prospecting, to fund the development of its Nolans Project.

Whitebark Energy’s fresh petrophysical analysis reveals significant dry gas zones in its Warro Gas Field, boosting its commercial prospects and prompting a $750,000 capital raise to fast-track development.

Centuria Industrial REIT has secured a landmark 10-year lease with Tesla, delivering a 133% re-leasing spread and deferring redevelopment plans, while pursuing a major data centre expansion in Victoria.

Albion Resources has delivered promising results from its maiden drilling campaign at Yandal West, revealing multiple high-grade gold zones and new target corridors that set the stage for an expanded exploration push.

HyTerra Ltd has successfully completed drilling and appraisal operations in Kansas, revealing elevated hydrogen and helium concentrations that reinforce the potential of its Nemaha Project. The company is advancing its US market presence with an OTCQB listing and strategic advisory appointments.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.